2021;12(1):1813. antibodies againstSARS\CoV\2 MCHr1 antagonist 2 virus. This detection method cansimultaneously detect IgG and IgM against SARS\CoV\2 virus within 18 minutes. This detection method has highsensitivity, stability and precision, and its specificity is higher than thatof colloidal gold. The dynamic variance of antibodiesdetected by this detection method can be consistent with the clinical CTresults, and can be used as a reference. 1.?INTRODUCTION Near the end of 2019, many cases of unexplained pneumonia occurred in Wuhan City, Hubei Province. The illness spread quickly throughout the city and eventually over?the entire country. 1 By early January 2020, it was confirmed that it was?an acute respiratory infection that was caused by novel severe acute respiratory syndrome coronavirus 2 (SARS\CoV\2), with the disease being named coronavirus disease 2019 (COVID\19). 2 However, the virus soon found its way around the world, and by the beginning of March 2020, the World Health Organization (WHO) officially labeled the disease as a pandemic. 3 As of April 2021, SARS\CoV\2 had spread to 223 countries, and there have been 147?539?302 confirmed cases of SARS\CoV\2, including 3?116?444 deaths. 4 SARS\CoV\2 occurred by human\to\human transmission and mostly affected elderly and immunocompromised persons. 5 The rapid spread of SARS\CoV\2 has caused considerable damage to public health and the economy. 6 , 7 In the absence of treatment for this virus, accurate and rapid diagnosis of SARS\CoV\2 is the cornerstone of the efforts to control the epidemic, and save people’s lives. Currently, the detection of viral nucleic acid real\time polymerase chain reaction (RT\PCR) has become the current standard diagnostic method for the diagnosis of COVID\19.8, 9 However, the performance of RT\PCR depends on many factors, such as the sample collection skill, sample type, different disease progression, and the quality and consistency of the PCR assay used.10, 11 Therefore, there is an urgent need for a rapid, simple to use, sensitive, and accurate test to identify infected patients of SARS\CoV\2 to prevent virus transmission. Early diagnosis, isolation, and treatment are essential to cure the disease and control the epidemic. Antibody detection is of great significance in the diagnosis of MCHr1 antagonist 2 infected patients, and helps to identify the stage of the infectious. 12 Based on these, we developed a magnetic chemiluminescence enzyme immunoassay test product, which could detect IgG and IgM simultaneously in human blood within 18?min. Here, we retrospectively described 456 serum samples through IgG/IgM antibody detection. All samples are from HwaMei Hospital, University of Chinese Academy of Sciences. This study may provide a reference for the clinical profile of SARS\CoV\2 patients confirmed by antibody detection, and further to investigate the potential relationship between immune antibodies and disease progression. 2.?METHODS 2.1. Data collection A total of 456 samples presented?to the hospital with laboratory\confirmed SARS\CoV\2 infection in HwaMei Hospital, University of Chinese Academy of Sciences, Zhejiang, China, by?April 2, 2020. The diagnosis of SARS\CoV\2 was based on guidelines issued by the National Health Commission of the People’s Republic of China and the interim guidance from the World Health Organization. All enrolled patients were confirmed to be infected with SARS\Cov\2 by RT\PCR of samples taken from upper nasopharyngeal swabs. Information was collected on dates of illness onset, clinical characteristics, chest computed tomographic (CT) scan. The 456 blood samples collected during the hospitalization were tested for IgG and IgM levels against SARS\CoV\2. Control blood samples from normal people with non\epidemiological history. The plasma samples were separated after centrifugation MCHr1 antagonist 2 at 3000?rpm for 5?min, and then frozen and stored at ?70. 2.2. Antibody detection The SARS\CoV\2 antibodies (IgG and IgM) of the subjects were detected using the SARS\CoV\2 IgG/IgM test kit by Ningbo Institute of life and Health Industry, University of Chinese Academy of Sciences. The IgG and IgM detection was developed based on a magnetic chemiluminescence enzyme immunoassay. Antibody levels are presented as the measured chemiluminescence values divided by the cutoff. The cutoff value for a positive result sample with IgG and IgM concentration more than equal to 278.8 and 6.6?U/ml are considered positive. The tests were conducted on an automated magnetic chemiluminescence analyzer (The Real Express\6) according to the manufacture’s instructions. All tests were performed TSPAN32 under strict biosafety conditions. The dynamics of antibodies with the disease progression were analyzed. 2.3. Stability of the SARS\CoV\2 antibody test kit To establish the stability of the kit, two samples were stored for.